Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1241 in Combination with Efruxifermin Shows Enhanced ...

A pretreatment step could help transplanted pancreatic islets survive longer in patients with type 1 diabetes, according to a new preclinical study ...

(Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics.

The webcast of the live call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website for ...

A vaccine developed by University of Georgia researchers successfully protects against and treats vaginal yeast infections in ...

Poster Presentation – “Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity (DIO) Mouse Model as Demonstrated by Weight Loss, Restored Hormonal ...

This valuable study presents a novel approach to enhance the therapeutic potential of mesenchymal stromal cells (MSCs) by genetically modifying their glycogen synthesis pathway, resulting in increased ...

Diabetes affects the body’s ability to control glucose, often causing excess glucose to build up in the bloodstream. Staph feeds off these high sugar levels, allowing it to reproduce more rapidly.

These drugs, which mimic the gut hormone glucagon-like peptide-1 (GLP-1), can help treat those with type 2 diabetes by stimulating the production of insulin and improving the function of beta cells.

Tests in mouse models of diabetes suggests that an experimental drug could help 'regrow' insulin-producing beta cells, thereby reversing the disease. Medical News Today Health Conditions ...

“As we advance our Rejuva program through preclinical development, we now observe that a single-dose administration of a human GLP-1 transgene (as in RJVA-001) can achieve durable lowering of blood ...